Navigation Links
Chay Enterprises Inc. Completes Merger With Repurposed Drug Developer Ampio Pharmaceuticals, Inc.
Date:3/4/2010

LITTLETON, Colo., March 4 /PRNewswire-FirstCall/ -- Chay Enterprises, Inc. (OTC Bulletin Board: CHYE) is pleased to announce today that the company has merged with DMI Life Sciences, Inc to form Ampio Pharmaceuticals, Inc. Ampio Pharmaceuticals will trade on the NASDAQ BB under the symbol CHYE.  "We have asked FINRA to change our symbol," said Don Wingerter, Ampio Pharmaceuticals' CEO, "and expect to be trading under our new symbol in less than thirty days."

"Ampio Pharmaceuticals' management has extensive experience in drug discovery and development, and has created a substantial pipeline of pharmaceuticals that address significant, unmet medical needs.  These pharmaceutical developments are in the category of so-called 'Repurposed Drugs,' pharmaceuticals previously shown to be safe and effective treatments in distinct therapeutic categories," said Mr. Wingerter.  "By entering the public space we will have access to capital to advance our pipeline and a public forum to educate patients and showcase our commercialization activities."

Dr. David Bar-Or, Ampio Pharmaceuticals' founder and Chief Scientific Officer, stated, "I have been working for over 30 years on finding solutions to important diseases that can impact an aging population. My role as the Director of Trauma Research at two major Colorado Level One Trauma Centers has given me the unique opportunity to study a variety of diseases in both clinical and research settings."

Ampio Pharmaceuticals discovers and develops innovative proprietary drugs for metabolic disease, eye disease, kidney disease, inflammation and CNS disease.  The company develops Repurposed Drugs because they have strong potential to be safe and effective while their shorter development times can significantly increase near-term value.  The product pipeline includes new uses for previously approved drugs, some of which are now starting clinical trials, and new molecular entities ("NMEs"). A key strategy includes actively exploring partnership, licensing and other collaboration opportunities to maximize the company's product development programs.  By concentrating on development of Repurposed Drugs, approval timelines, costs and risk of clinical failure are reduced due to the fact that the Repurposed Drug has previously been found to be safe and effective, generally at higher dosage rates, in distinct therapeutic categories."

Safe Harbor Statement

Certain of the above statements contained in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements are within the meaning of that term in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Readers are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those indicated in the forward-looking statements as a result of various factors.

SOURCE Ampio Pharmaceuticals, Inc.

Back to top

RELATED LINKS
http://www.ampiopharma.com

'/>"/>

SOURCE Ampio Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. New Small and Medium Sized Enterprises Join TI Pharma by Signing Two New Projects
2. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
5. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
6. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
7. QuatRx Completes Patient Enrollment in Phase 3 Study of Ophena(TM) in Women with Postmenopausal Vaginal Syndrome
8. CryoCor Completes Enrollment of Pivotal Clinical Study for Atrial Fibrillation
9. Anesiva Completes Enrollment in Phase 3 Clinical Trial of Zingo(TM) to Treat Pain Associated With Venous Access Procedures in Adults
10. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
11. Cadence Pharmaceuticals Completes Enrollment of Pivotal Phase III Trial for Intravenous Acetaminophen Ahead of Schedule
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2017)... -- NDS received FDA 510(k) clearance in May 2017 for its highly ... designed for endoscopy environments. An innovative secondary monitor solution, ZeroWire ... support the improvement of patient outcomes, procedural efficiency, and the lowering ... ... ...
(Date:10/4/2017)... 4, 2017  South Korean-based healthcare product Development Company ... "cprCUBE" on Kickstarter. The device will educate the user ... with better efficiency compared to the dated and pricey ... on efficacy of the compression for a more informed ... goal to raise $5,000. ...
(Date:10/2/2017)... 2017  Eli Lilly and Company (NYSE: ... third quarter of 2017 on Tuesday, October 24, 2017. ... day with the investment community and media to further ... call will begin at 9 a.m. Eastern time. Investors, ... webcast of the conference call through a link that ...
Breaking Medicine Technology:
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... Apple ... care services, staged a mock evacuation of the facility as part of a disaster ... Fire Department, Echo Hose EMS and Shelton City Emergency Manager, as well as the ...
(Date:10/13/2017)... , ... October 13, 2017 , ... Global Healthcare Management’s ... Alexandria Park in Milford, NJ. This free event, sponsored by Global Healthcare Management’s ... The fun run is geared towards children of all ages; it is a ...
(Date:10/13/2017)... ... October 13, 2017 , ... “The Journey: From the ... danger possible to save lost souls in the Philippines. “The Journey: From the Mountains ... a dedicated teacher of the Bible. She has taught all ages and currently teaches ...
(Date:10/12/2017)... ... October 12, 2017 , ... Planet Fitness, one of the largest and ... plans to open a flagship location in Covington, LA at 401 N. U.S. Highway ... store next to Office Depot in the Holiday Square shopping center. Its location allows ...
(Date:10/12/2017)... ... 2017 , ... Asante, a nationally recognized health system in ... existing home health joint venture through an agreement, effective October 1, 2017, to ... home health company with Asante, delivering clinically integrated care, for the past eight ...
Breaking Medicine News(10 mins):